The main point of the letter by Ohno et al. is that styrene oligomers have no estrogenic activity, that our statement about \"some styrene oligomers having binding affinity for hERα\" was inaccurate, and that the MCF-7 cell proliferation assay is useless in detecting estrogenicity.

It seems that Ohno et al. have misunderstood our article. We are confident that the results of the MCF-7 cell proliferative assay and the binding assay of styrene oligomers to hERα in our paper are accurate.

The inhibition of fluorescence-labeled E~2~ binding to hERα by styrene oligomers tested is shown in [Figure 3](#f3){ref-type="fig"} of our paper ([@r1]). The inhibition by styrene trimers 1a-phenyl-4e-(1´-phenylethyl)tetralin (ST-3) and 1e-phenyl-4a-(1´-phenylethyl)tetralin (ST-4) was detected at ≥ 5 x 10^-7^ M, and the inhibition by styrene trimers 2,4,6-triphenyl-1-hexene (ST-1), 1a-phenyl-4a-(1´-phenylethyl)tetralin (ST-2), and 1e-phenyl-4e-(1´-phenylethyl)tetralin (ST-5) was detected at ≥ 5 x 10^-6^ M, both sufficiently soluble concentrations. This means that ST-1, ST-2, ST-3, ST-4, and ST-5 bound to hERα at \"not high\" concentrations. The maximum inhibition by styrene trimers (ST-1, ST-2, ST-3, ST-4, and ST-5) was detected at 5 x 10^-5^ M; this concentration is relatively low. Although the maximum inhibition by styrene dimers 1,3-diphenyl propane, (SD-1), 2,4-diphenyl-1-butene (SD-2), *cis*-1,2-diphenyl cyclobutane (SD-3), and *trans*-1,2-diphenyl cyclobutane (SD-4) was detected at 5 x 10^-4^ M, these styrene trimers and dimers were almost soluble at 5 x 10^-5^ M and 5 x 10^-4^ M, respectively. It is important that the inhibition hardly increased at each 10-times-higher concentration at which chemicals tested were partially insoluble. This result indicates that the soluble chemicals reacted with hER in saturated solution, and insoluble compounds did not influence the binding. In Table 1 of their letter, Ohno et al. did not clarify the solubility of the compounds. It appears that the compounds were dissolved in water because of the extremely low solubility. In our study we dissolved the compounds in DMSO\--the styrene dimers at 100,000 µmol/L and the styrene trimers at 10,0000 µmol/L, except for ST-2 (1,000 µmol/L). Ohno et al. should have included the concentrations of the saturating chemicals in the reaction solutions of each method in their Table 1, because when various concentrations of the chemical solvents (DMSO) are added to the reaction solutions, the solubility will become much higher.

If our binding assay indicated false positives in the range of concentrations in which test chemicals were insoluble, the inhibition by 1e,3e,5a-triphenylcyclohexane (ST-6) and 1e,3e,5e-triphenylcyclohexane (ST-7) would also increase, but no binding activity was observed for ST-6 and ST-7 at any concentration tested. This method (Ohno et al.\'s Method B) showed an increase in the inhibition of binding by some soluble styrene oligomers but no effect by the same chemicals at insoluble concentrations. Ohno et al.\'s Method B showed no ED~30~ values of the styrene oligomers at \> 10 µmol/L. Therefore, Ohno et al.\'s Method B also indicated no effect by the styrene oligomers at insoluble concentrations except testosterone, 5α-dihydrotestosterone, vitamin D~3~, and naphthalene. It seems that testosterone, 5α-dihydrotestosterone, vitamin D~3~, and naphthalene used by Ohno et al. had special characteristics for the competitive binding assay kit (Wako, Osaka, Japan).

The MCF-7 cell proliferation assay is a recognized method for estrogenic screening. Ohno et al. overemphasize other growth factors. All of the styrene oligomers we tested did not have proliferative activity ([@r1]). ST-6 and ST-7 had no proliferative activity at all, but the proliferative potency of ST-3 and ST-4 was comparable with that of bisphenol A. Moreover we confirmed that OH-tamoxifen, an antagonist, inhibited cell proliferation by ST-1, ST-3, ST-4, ST-5, SD-3, and SD-4 ([@r2]).

Recently, we reported that ST-1 and ST-4 were estrogenic in the reporter gene assay using MVLN cells established by stable transfection with the luciferase gene ([@r3]). Moreover we found that some other styrene oligomers were also estrogenic in this reporter gene assay ([@r2]).

We are confident that our paper ([@r1]) does not include any inaccurate results.

Corrections and Clarifications
==============================

In \"3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) and Mutagenic Activity in Massachusetts Drinking Water\" by Wright et al. \[*Environ Health Perspect* 110:157-164 (2002)\], there are two errors in \"Methods.\" In lines 12-16 of the second paragraph describing analytical protocol, \"700°C\" should be \"70°C\" and \"600 mg/L aqueous NaHCO~3~\" should be \"600 µg/L 2% aqueous NaHCO~3~.\" The correct sentences are as follows:

> The solution was heated to 70°C to accelerate the reaction. The mixture was neutralized by addition of 600 µg/L 2% aqueous NaHCO~3~ and extracted twice with 600 µL *n*-hexane.

*EHP* regrets the errors.

In \"Certain Styrene Oligomers Have Proliferative Activity on MCF-7 Human Breast Tumor Cells and Binding Affinity for Human Estrogen Receptor α\" by Ohyama et al. \[*Environ Health Perspect* 109:699-703 (2001)\], the grids in [Figure 3](#f3){ref-type="fig"} are incorrect. The corrected figure appears below. *EHP* regrets any confusion caused by the incorrect grids.

![The inhibition of fluorescence-labeled E~2~ binding to hERα by various concentrations of styrene oligomers. Percent of inhibition was calculated as \[1 -- (optical density in the presence of competitor) ÷ (optical density in the absence of competitor)\] × 100. Each point is the mean ± SD of two independent assays performed in duplicate. \*Significantly different from hormone-free control (p \< 0.01).](ehp.110-a385.g001){#f3}
